HemoClear: A Practical and Cost-Effective Alternative to Conventional Convalescent Plasma Retrieval Methods.

Area of Science:

• Virology
• Transfusion Medicine
• Medical Devices

Background:

• Convalescent plasma is a proven treatment for viral infections, including SARS-CoV-2.
• The COVID-19 pandemic revealed limitations in traditional plasmapheresis, emphasizing the need for accessible alternatives.
• Hospitals require self-sufficient methods for plasma collection and transfusion.

Purpose of the Study:

• To evaluate the practicality and efficacy of a membrane-based bedside plasmapheresis device (HemoClear).
• To assess the potential of HemoClear in resource-constrained settings during public health emergencies.
• To review HemoClear's role in expediting convalescent plasma procurement.

Main Methods:

• An open-label, non-randomized prospective trial was conducted in Suriname in 2021.
• The study involved evaluating the HemoClear device for bedside plasma harvesting and transfusion.
• Data collection focused on the device's usability and clinical outcomes.

Main Results:

• The HemoClear device demonstrated practicality and efficacy in a low-to-middle-income country setting.
• The bedside approach facilitated on-site plasma collection and transfusion.
• The method proved suitable for use during the COVID-19 pandemic.

Conclusions:

• The HemoClear device offers a viable, cost-effective alternative to conventional plasmapheresis.
• Bedside plasmapheresis can enhance hospital self-sufficiency in plasma availability.
• This technology holds significant potential for managing viral outbreaks in resource-limited environments.